CD47 and neoplasm: Doxorubicin, cisplatin, and the EGFR tyrosine kinase inhibitor, Osimertinib, have been found to potentiate the efficacy of CD47 blockade by upregulating pro-phagocytic signals in preclinical tumor models [228,289,290,291].